Radiosurgery and Avastin for Recurrent Malignant Gliomas
The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).
• History of malignant glioma (WHO Grade III or IV) of the brain treated with some combination of surgery, biochemotherapy and conventionally fractionated external beam radiotherapy
• Radiotherapy completed at least 6 months prior to recurrence
• Age 18 years and older
• New or enlarging contrast-enhancing and/or 18FDG-avid nodule, at least 1 cm diameter
• Estimated life expectancy of 3 months or longer